chitosan
cs
surfacemodifi
poli
llactidecoglycolid
plga
nanospher
ns
sirna
deliveri
system
evalu
vitro
sirnaload
plga
ns
prepar
emuls
solvent
diffus
esd
method
physicochem
properti
ns
investig
level
target
protein
express
sirna
uptak
examin
cell
csmodifi
plga
ns
exhibit
much
higher
encapsul
effici
unmodifi
plga
ns
plainplga
ns
csmodifi
plga
ns
show
posit
zeta
potenti
plainplga
ns
neg
charg
sirna
uptak
studi
observ
confoc
leaser
scan
microscopi
clsm
indic
sirnaload
csmodifi
plga
ns
effect
taken
cell
plainplga
ns
effici
differ
sirna
prepar
compar
level
target
protein
express
genesilenc
effici
csmodifi
plga
ns
higher
prolong
plainplga
ns
nake
sirna
result
correl
clsm
studi
may
due
higher
cellular
uptak
csmodifi
plga
ns
due
electrostat
interact
conclud
csmodifi
plga
ns
contain
sirna
could
provid
effect
sirna
deliveri
system
recent
effort
design
molecular
biolog
tool
focus
rna
interfer
rnai
effect
knock
express
target
protein
small
interf
rna
sirna
small
doublestrand
rna
dsrna
oligonucleotid
without
overhang
substrat
rnainduc
silenc
complex
transfect
cell
synthet
sirna
strongli
inhibit
express
target
protein
mammalian
cell
applic
sirna
human
therapi
attract
much
attent
although
deliveri
sirna
appropri
cell
tissu
organ
remain
major
challeng
ideal
gene
deliv
carrier
safe
transport
genet
materi
without
toxic
effect
induc
immun
respons
research
use
viral
vector
retrovirus
adenovirus
liposom
recent
mani
nonvir
vector
report
modifi
fusogen
peptid
cation
lipid
cation
polym
other
howev
cation
compound
show
cytotox
effect
polymer
nanospher
ns
use
drug
deliveri
due
high
stabil
easili
taken
cell
endocytosi
target
specif
tissu
organ
adsorpt
bind
ligand
attach
surfac
particl
particular
biodegrad
nanospher
avail
deliv
drug
degrad
pass
requir
specif
site
among
poli
lactid
pla
poli
llactidecoglycolid
plga
approv
fda
certain
human
clinic
use
degrad
time
plga
alter
day
year
vari
molecular
weight
lactic
acid
glycol
acid
ratio
copolym
nanospher
structur
plga
nanospher
suggest
good
gene
deliveri
carrier
safeti
properti
sustain
releas
develop
emuls
solvent
diffus
esd
method
water
prepar
plga
ns
advantag
esd
method
ns
prepar
simpl
process
mild
condit
without
sonic
plga
ns
platform
encapsul
wide
varieti
nucleic
acid
eg
plasmid
dna
antisens
oligonucleotid
sirna
gene
deliveri
establish
use
esd
method
also
investig
use
cation
charg
csmodifi
plga
ns
improv
bioavail
pulmonari
plasmid
dna
pdna
gene
deliveri
system
vitro
vivo
manuscript
submit
number
pulmonari
diseas
candid
pulmonari
gene
deliveri
lung
cancer
influenza
viru
infect
respiratori
syncyti
viru
infect
rsv
sever
acut
respiratori
syndrom
sar
attract
particular
attent
target
sirna
therapi
csmodifi
plga
ns
previous
test
pdna
deliveri
pulmonari
gene
therapi
adapt
sirna
barrier
deliveri
similar
aim
studi
evalu
sirnaload
plga
ns
cellular
uptak
rnai
effect
use
human
lung
adenocarcinoma
cell
vitro
plga
lactid
glycolid
mw
purchas
wako
osaka
japan
polyvinylalcohol
pva
purchas
kuraray
osaka
japan
chitosan
mw
deacetyl
degre
obtain
katakurachikkarin
tokyo
japan
fluoresc
dye
coumarin
laser
grade
diethylamin
coumarin
purchas
mp
biomed
solon
oh
human
lung
adenocarcinoma
cell
purchas
riken
gene
bank
ibaraki
japan
dulbecco
modifi
eagl
medium
dmem
fetal
bovin
serum
fb
purchas
gibco
basel
switzerland
mannitol
kishida
chemic
co
ltd
osaka
japan
use
cryoprotect
reconstitut
sirnaload
plga
ns
redispers
aqueou
medium
dotap
sigma
st
loui
mo
use
cation
complex
agent
prepar
sirnaload
plga
ns
model
sirna
use
anneal
sirna
target
firefli
luciferas
lucsirna
sens
cuuacgcug
antisens
dtdtgaaugcgacucaugaa
dharmacon
inc
chicago
il
sirna
target
protein
sens
antisens
dharmacon
anneal
sirna
target
protein
kinas
c
alpha
pkcsirna
sens
antisens
ambion
austin
tx
use
control
sirna
chemic
obtain
commerci
highest
avail
analyt
grade
cell
grown
dmem
supplement
fb
lgml
penicillin
streptomycin
humidifi
incub
co
confluent
growth
cell
trypsin
seed
plate
experi
establish
cell
stabli
express
firefli
luciferas
cell
transfect
plasmid
dna
encod
firefli
luciferas
control
cytomegaloviru
immedi
earli
promot
complex
lipofectamin
invitrogen
carlsbad
ca
cell
treat
medium
contain
mgml
geneticin
sigma
cell
pick
examin
luciferas
activ
describ
signific
differ
growth
rate
cell
vitro
addit
microscop
ident
sirnaload
plga
ns
prepar
emuls
solvent
diffus
method
water
first
prepar
sirnadotap
complex
milliq
water
contain
lg
sirna
ad
volum
milliq
water
contain
lg
dotap
solut
stir
plga
mg
sirnadotap
complex
solut
dissolv
aceton
ml
prepar
fluorescencelabel
plga
ns
lg
ad
organ
solut
dissolv
plga
sirna
result
organ
solut
pour
ml
aqueou
pva
solut
wv
stir
rpm
use
propellertyp
agit
three
blade
entir
dispers
system
centrifug
min
resuspend
milliq
water
ml
volum
mannitol
solut
wv
cryoprotect
ad
ns
suspens
result
dispers
dri
freez
dri
prepar
csmodifi
plga
ns
chitosan
wv
acet
buffer
ph
pva
wv
distil
water
mix
solut
use
dispers
phase
emuls
solvent
diffus
process
studi
sirna
complex
sirnadotap
sirnacsmodifi
plga
ns
evalu
vitro
prepar
sirnadotap
complex
milliq
water
contain
lg
sirna
ad
volum
milliq
water
contain
lg
dotap
solut
stir
sirnan
complex
milliq
water
use
suspend
mg
blank
empti
csmodifi
plga
ns
mgml
ad
rapidli
equival
volum
milliq
water
contain
sirna
mgml
stir
particl
size
zeta
potenti
measur
perform
use
zetas
hsa
malvern
instrument
uk
particl
size
measur
photon
correl
spectroscopi
pc
zeta
potenti
determin
base
electrophoret
mobil
ns
aqueou
medium
surfac
topolog
shape
nanospher
observ
scan
electron
microscop
sem
nihon
denshi
japan
amount
sirna
entrap
ns
analyz
dissolv
ns
mg
acetonitril
ml
acet
buffer
ph
ml
contain
wv
sd
ad
precipit
polym
dissolv
sirna
result
aqueou
mixtur
solut
centrifug
min
sirna
content
supernat
determin
fluoresc
measur
fluoresc
spectrophotomet
excit
wavelength
nm
emiss
wavelength
nm
hitachi
tokyo
japan
load
effici
sirna
calcul
follow
equat
load
effici
weight
nucleic
acid
nss
weight
nucleic
acid
formul
system
releas
properti
sirna
ns
investig
vitro
mg
sampl
ns
dispers
ml
pb
ph
test
tube
shaken
horizont
differ
resid
time
buffer
separ
ns
centrifug
g
min
analyz
amount
releas
sirna
determin
ns
resuspend
fresh
medium
cell
grown
labtek
ii
chamber
slide
nalg
nunc
intern
rochest
ny
densiti
cell
well
experi
conduct
cell
form
confluent
monolay
determin
light
microscopi
growth
medium
replac
suspens
differ
prepar
serumfre
dmem
system
incub
h
incub
cell
monolay
differ
sirna
prepar
monolay
fix
paraformaldehyd
wash
pb
cover
slip
mount
slide
use
slowfad
antifad
kit
molecular
probe
eugen
fix
cell
observ
confoc
laser
scan
microscop
carl
zeiss
lsm
goettingen
germani
equip
zeiss
oil
immers
object
len
use
argonion
laser
nm
helium
neon
laser
nm
factin
stain
fix
cell
permeabil
triton
pb
min
incub
alexa
fluor
phalloidin
molecular
probe
pb
min
room
temperatur
wash
pb
cover
slip
mount
slide
cell
seed
h
transfect
densiti
cell
per
well
plate
experiment
schedul
shown
fig
growth
medium
replac
suspens
differ
sirna
prepar
serumfre
dmem
nm
sirna
system
incub
h
ns
suspens
replac
fb
contain
dmem
system
incub
day
cultur
medium
renew
two
day
variou
time
transfect
cell
rins
three
time
icecold
pb
solubil
ml
report
cell
lysi
reagent
promega
madison
wi
centrifug
min
supernat
collect
analyz
luciferas
activ
typic
experi
luciferas
assay
buffer
promega
ad
supernat
tube
luciferas
activ
sampl
measur
glomax
luminomet
promega
cellular
protein
content
determin
bca
protein
assay
pierc
rockford
il
convert
data
luciferas
activ
rlu
per
milligram
protein
result
express
percentag
control
five
sirna
prepar
evalu
vitro
nake
sirna
sirnadotap
complex
sirnadotapload
unmodifi
plga
ns
plainplga
ns
sirnadotapload
plga
ns
modifi
chitosan
csmodifi
plga
ns
sirnac
modifi
blankplga
ns
complex
sirnan
complex
variou
formul
factor
physicochem
properti
ns
play
key
role
biolog
applic
import
factor
influenc
transfect
cellular
uptak
particl
size
surfac
properti
ns
physicochem
properti
sirna
prepar
shown
tabl
dotap
commerci
cation
lipid
use
transfect
reagent
could
easili
form
submicrons
complex
sirna
complex
high
posit
zeta
potenti
mv
sirnaload
plga
ns
prepar
use
esd
method
techniqu
simpl
process
use
mild
condit
without
sonic
may
degrad
nucleic
acid
prepar
sirnaload
plga
ns
complex
cation
compound
use
esd
method
plga
ns
prepar
emuls
solvent
diffus
method
gave
yield
ns
excess
particl
size
plga
ns
prepar
esd
method
sirnaload
plga
ns
nm
shown
fig
topolog
sirnaload
plga
ns
observ
sem
spheric
smooth
surfac
homogen
submicrons
rang
sirnaload
plga
ns
without
ad
mannitol
cryoprotect
aggreg
lyophil
data
shown
littl
dispar
size
size
distribut
nanoparticl
contain
cryoprotect
lyophil
provid
dispers
lyophil
ns
aqueou
solut
mannitol
requir
cryoprotect
zeta
potenti
plainplga
ns
neg
due
dissoci
carboxyl
group
plga
neg
zeta
potenti
sirnaload
plga
ns
prove
sirnadotap
complex
posit
zeta
potenti
encapsul
plga
ns
adsorb
surfac
plga
ns
csmodifi
plga
ns
could
prepar
ad
cs
solut
outer
phase
pva
solut
csmodifi
plga
ns
posit
charg
due
proton
amino
group
zeta
potenti
shift
posit
valu
due
effect
cs
adsorb
surfac
plga
ns
particl
size
csmodifi
plga
ns
increas
molecular
layer
cs
modifi
surfac
plga
ns
also
check
composit
csmodifi
plga
ns
use
fitcconjug
cs
cs
adsorb
ns
surfac
ww
ns
data
shown
modifi
cs
encapsul
effici
increas
effect
modifi
cs
load
effici
might
caus
ionic
interact
sirna
cs
prevent
leakag
sirna
emuls
droplet
diffus
process
zeta
potenti
sirnan
complex
decreas
compar
csmodifi
plga
ns
sirna
neg
charg
deriv
dissoci
phosphat
group
drug
releas
nanoparticul
matrix
system
drug
uniformli
enclos
gener
occur
diffus
eros
matrix
sever
paramet
also
affect
drug
releas
rate
matrix
system
exampl
molecular
weight
lactid
glycolid
ratio
polym
use
matrixform
system
import
impact
drug
releas
shown
fig
sirna
releas
exhibit
biphas
releas
pattern
character
initi
releas
follow
slower
releas
phase
initi
burst
releas
sirna
plainplga
ns
shown
initi
burst
drug
releas
significantli
prolong
five
day
sirna
still
remain
plainplga
ns
sustain
releas
later
stage
due
diffus
sirna
plga
matrix
well
eros
ns
modifi
ns
chitosan
alter
drug
releas
pattern
howev
plga
ns
modifi
chitosan
reduc
initi
burst
sirna
releas
prolong
releas
later
stage
interact
sirna
chitosan
might
caus
sirna
remain
surfac
plga
ns
therefor
differ
nanostructur
design
sirnaload
plga
ns
might
requir
control
desir
releas
pattern
chang
surfac
properti
howev
adsorpt
sirna
surfac
csmodifi
plga
ns
unlik
found
sirna
adsorb
blank
ns
h
report
sirnacontrol
releas
carrier
use
plga
especi
mani
expert
publish
research
plga
microspher
capabl
longterm
drug
releas
sirna
releas
plga
microspher
prolong
month
comparison
submicrons
ns
howev
micros
particl
difficult
penetr
deep
tissu
uptak
cell
microspher
may
limit
applic
due
larg
size
cellular
uptak
differ
sirna
red
fluoresc
prepar
evalu
visual
use
confoc
laser
scan
microscopi
clsm
shown
fig
nake
sirna
ad
cell
fluoresc
observ
cell
shown
fig
sirna
hydrophil
polym
strong
neg
charg
deriv
phosphat
group
make
difficult
penetr
nake
sirna
cell
without
transfect
reagent
could
observ
cell
stain
alexa
fluor
phalloidin
clarifi
locat
cell
use
dotap
transfect
reagent
fig
dotap
cation
lipid
easili
form
electrostat
complex
sirna
clsm
cell
expos
fluoresc
label
plga
ns
load
sirna
demonstr
fluoresc
activ
cell
incub
plga
ns
suspens
fig
green
fluoresc
plga
ns
imag
chang
yellow
color
provid
better
illustr
coloc
plga
ns
sirna
vitro
cytotox
test
plga
ns
neg
affect
viabil
cell
uptak
experi
imag
shown
zsection
center
cell
indic
fluoresc
observ
result
plga
ns
local
insid
cell
found
incub
cellular
uptak
sirna
use
differ
sirna
formul
increas
deliveri
system
compar
nake
sirna
show
neglig
cellular
uptak
suggest
hypothesi
cellular
uptak
restrain
factor
sirna
therapeut
gener
colloid
drug
deliveri
system
appear
potenti
candid
improv
situat
uptak
fluoresc
plainplga
ns
csmodifi
plga
ns
could
observ
cytosol
analyz
clsm
imag
cell
suggest
plga
ns
intern
cell
sirna
could
also
observ
cytosol
plga
ns
coloc
plga
ns
fluoresc
appear
yellow
fluoresc
consequ
plga
ns
intern
therefor
sirnaload
plga
ns
taken
cell
sirna
intern
encapsul
releas
sirna
ns
uptak
csmodifi
plga
ns
show
higher
uptak
cell
plainplga
ns
zeta
potenti
csmodifi
plga
ns
prove
posit
charg
result
suggest
cation
cs
surfac
ns
enhanc
associ
csmodifi
plga
ns
neg
charg
cell
membran
electrostat
interact
ns
cellular
uptak
might
increas
case
sirnan
complex
cellular
uptak
decreas
compar
csmodifi
plga
ns
sirna
releas
sirnan
complex
rapid
shown
fig
therefor
could
observ
cytosol
plga
ns
howev
investig
regard
mechan
nanoparticl
uptak
kinet
drug
uptak
retent
cell
help
order
establish
effici
plga
ns
sirna
deliveri
normal
cell
show
signific
luciferas
activ
sampl
luciferas
activ
cell
proport
increas
accord
number
cell
indic
luciferas
activ
could
use
indic
number
cell
shown
fig
luciferas
genesilenc
effici
csmodifi
plga
ns
higher
prolong
plainplga
ns
result
correl
clsm
studi
might
caus
higher
cellular
uptak
abil
csmodifi
plga
ns
due
electrostat
interact
contrast
sirna
effect
plainplga
ns
observ
sirna
encapsul
plainplga
ns
taken
cell
littl
almost
sirna
encapsul
plainplga
ns
releas
initi
burst
furthermor
initi
burst
sirna
easili
releas
form
plainplga
ns
nake
sirna
downregul
product
luciferas
gene
sirnadotap
complex
use
posit
control
show
strong
initi
suppress
regul
effect
becam
gradual
weaker
suppress
pattern
quit
differ
csmodifi
plga
ns
suppress
pattern
sirnaload
csmodifi
plga
ns
initi
weak
gradual
becam
stronger
phenomena
could
account
sustain
sirna
releas
plga
ns
cytosol
sustain
releas
profil
sirna
csmodifi
plga
ns
confirm
fig
adsorpt
sirna
plga
ns
surfac
sirnan
complex
maintain
genesilenc
effect
sirna
releas
plga
ns
surfac
rapid
fig
result
low
nonsustain
genesilenc
effect
contrast
control
sirnaload
plga
ns
empti
csmodifi
plga
ns
show
signific
differ
luciferas
activ
compar
treatment
cell
shown
fig
though
sirnacation
lipid
complex
lipoplex
easili
transfect
transfect
reagent
avail
commerci
may
cytotox
provid
control
sustain
releas
exampl
cation
lipid
known
toxic
effect
induc
immun
respons
unstabl
high
ionic
condit
plga
approv
us
food
drug
administr
fda
limit
clinic
use
chitosan
surfac
modifi
enhanc
transport
ns
cell
biocompat
biodegrad
previous
found
csmodifi
plga
ns
show
cytotox
effect
cell
contrast
pdnadotap
complex
manuscript
submit
possibl
plga
ns
use
high
dose
sirna
therapi
due
lack
side
effect
system
also
advantag
sirna
protect
rnase
drug
releas
sirna
releas
pattern
control
load
plga
ns
sirna
effect
vari
pattern
creat
combin
carrier
show
effect
first
stage
carrier
show
effect
later
stage
furthermor
ns
storag
long
time
possibl
powder
plga
ns
freez
dri
high
stabil
suggest
possibl
csmodifi
plga
ns
appli
therapeut
variou
diseas
use
sirna
csmodifi
plga
ns
might
develop
nonvir
vector
sirna
deliveri
investig
requir
optim
sirna
effect
appli
present
system
gene
therapi
sirnaload
plga
ns
pulmonari
gene
deliveri
system
prepar
vitro
activ
evalu
csmodifi
plga
ns
highli
recommend
carrier
sirna
deliveri
due
high
interact
cell
safeti
term
cytotox
nontox
formul
evalu
vitro
vivo
abil
provid
sirna
carrier
purpos
gene
therapi
